Education
About Us
Working with TipRanks
Follow Us
Biote Corp. (BTMD)
:BTMD
BTMD Stock Chart & Stats
$2.74
-$0.14(-2.36%)
At close: 4:00 PM EST
$2.74
-$0.14(-2.36%)
Day’s Range― - ―
52-Week Range$2.71 - $6.98
Previous CloseN/A
Volume19.10K
Average Volume (3M)109.16K
Market Cap
$135.46M
Enterprise Value$267.94M
Total Cash (Recent Filing)$19.60M
Total Debt (Recent Filing)$107.89M
Price to Earnings (P/E)3.0
Beta0.94
Next Earnings
Nov 05, 2025EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding33,280,228
10 Day Avg. Volume108,370
30 Day Avg. Volume109,162
Financial Highlights & Ratios
PEG Ratio-2.30
Price to Book (P/B)-2.00
Price to Sales (P/S)1.07
P/FCF Ratio5.46
Enterprise Value/Market Cap1.98
Enterprise Value/Revenue1.35
Enterprise Value/Gross Profit1.87
Enterprise Value/Ebitda4.76
Forecast
1Y Price Target
$4.88Price Target Upside78.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Business GrowthThe supplements business was a bright spot, growing by 25% due to moving to Amazon.
Market OpportunityThe market opportunity remains attractive and the end consumer remains loyal to BTMD's products even in a choppy macro backdrop.
ValuationAnalyst maintains a Buy rating given the potential for the turnaround and inexpensive valuation.
Bears Say
Financial GuidanceManagement lowered both revenue and EBITDA outlook and now expects revenue above $190mm vs. $202-$208mm prior and adj. EBITDA above $50mm vs. $59-$64mm prior.
Revenue DeclineProcedure revenue declined by -8.4% reflecting lower new clinic growth, higher than normal attrition of established clinics, and lower procedure volume.
Software TransitionOngoing software transition issues will linger, and it will likely take 2+ quarters for trends to start to show improvement.
biote News
BTMD FAQ
What was Biote Corp.’s price range in the past 12 months?
Biote Corp. lowest stock price was $2.71 and its highest was $6.98 in the past 12 months.
What is Biote Corp.’s market cap?
Biote Corp.’s market cap is $135.46M.
When is Biote Corp.’s upcoming earnings report date?
Biote Corp.’s upcoming earnings report date is Nov 05, 2025 which is in 6 days.
How were Biote Corp.’s earnings last quarter?
Biote Corp. released its earnings results on Aug 06, 2025. The company reported $0.1 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.02.
Is Biote Corp. overvalued?
According to Wall Street analysts Biote Corp.’s price is currently Undervalued.
Does Biote Corp. pay dividends?
Biote Corp. does not currently pay dividends.
What is Biote Corp.’s EPS estimate?
Biote Corp.’s EPS estimate is 0.08.
How many shares outstanding does Biote Corp. have?
Biote Corp. has 33,280,228 shares outstanding.
What happened to Biote Corp.’s price movement after its last earnings report?
Biote Corp. reported an EPS of $0.1 in its last earnings report, beating expectations of $0.08. Following the earnings report the stock price went down -24.352%.
Which hedge fund is a major shareholder of Biote Corp.?
Currently, no hedge funds are holding shares in BTMD
biote Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.88 (78.10% Upside)
$4.88 (78.10% Upside)
Blogger Sentiment
Bullish
BTMD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 152.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.81%
Trailing 12-Months
Company Description
Biote Corp.
Biote (BTMD) is a biotechnology company specializing in hormone optimization and personalized wellness solutions. The company focuses on developing and providing bioidentical hormone replacement therapies (BHRT) and related products aimed at improving the quality of life for individuals experiencing hormonal imbalances. Biote operates primarily in the healthcare sector, targeting both men and women, and offers a range of services including education, training, and support for healthcare providers in administering hormone therapies.
BTMD Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong performance in dietary supplements and cost management, alongside challenges in procedure revenue and clinic attrition. The strategic reorganization is expected to drive growth, but the impacts are yet to be realized. The flat overall revenue and adjusted guidance indicate ongoing challenges.View all BTMD earnings summariesBTMD Stock 12 Month Forecast
Average Price Target
$4.88
▲(78.10% Upside)
Technical Analysis
Concord Medical Services
―
Joint
―
Cryo-Cell International
―
DocGo
―
P3 Health Partners
―
Ownership Overview
43.49% Insiders
9.16% Mutual Funds
0.97% Other Institutional Investors
39.02% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---